Abstract

Background In chronic heart failure, several hormonal systems are activated with diagnostic and prognostic implications. We tested the hypotheses that serum Chromogranin-A (CgA)—a 49kDa acid protein present in the secretor granules of neuroendocrine cells—is increased in chronic heart failure and that CgA levels are a predictive factor for mortality.

Methods and Results In 160 patients with chronic heart failure, we measured serum CgA and other neuroendocrine hormones. The results showed that CgA is increased in chronic heart failure and the increase is related to the clinical severity of the syndrome: CgA levels in New York Heart Failure (NYHA) class II (median 146·9ng.ml−1, inter-quartiles 108·3–265·5) were significantly higher (P<0·05) than in class I (median 109·7ng.ml−1, inter-quartiles 96·7–137·6), and significantly lower (P<0·05) than in class III (median 279·0ng.ml−1, inter-quartiles 203·6–516·1). Class IV patients showed the highest serum levels of CgA (median 545·0ng.ml−1, inter-quartiles 231·8–1068·3), being statistically significantly different from class III patients (P<0·001). The association between survival and some recognized variables of prognostic significance, including CgA was also studied. The results showed that ejection fraction, noradrenaline, atrial natriuretic peptide, NYHA class and CgA were significant univariate prognosticators; however, in the multivariate analysis by the Cox proportional-hazard model, CgA and NYHA class were the only independent predictive factors for mortality (P<0·005, RR=1·22, 95% CI=1·06–1·41 andP =0·04, RR=1·58, 95% CI=1·02–2·46, respectively).

Conclusions CgA is a pro-hormone, precursor of several active fragments likely to exert biological effects in chronic heart failure. CgA serum levels are increased in patients with chronic heart failure and are a predictive factor for mortality.

f1
Correspondence: Prof. Roberto Ferrari, Dipartimento di Medicina Clinica e Sperimentale, Università di Ferrara, Corso Giovecca 203, 44100, Ferrara, Italy.

References

1
Levine
TB
, Francis GS, Goldsmith SR, Simon A, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.
Am J Cardiol
 .
1982
;
49
:
1659
–1666
2
Cody
RJ
, Atlas SA, Laragh JH. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.
J Clin Invest
 .
1986
;
78
:
1362
–1374
3
Packer
M
, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
Circulation
 .
1987
;
75
:
IV80
–92
4
Francis
GS
, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma noradrenaline, plasma renin activity, and congestive heart failure.
Circulation
 .
1993
;
87
:
VI40
–48
5
McMurray
JJ
, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure.
Circulation
 .
1992
;
85
:
1374
–1379
6
Omland
T
, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction.
Circulation
 .
1994
;
89
:
1573
–1579
7
Pernow
J
, Lundberg JM, Kaijser L. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man.
Clin Physiol
 .
1986
;
6
:
561
–578
8
Pousset
F
, Masson F, Chavirovskaia O. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure.
Eur Heart J
 .
2000
;
21
:
1009
–1014
9
Ferrari
R
, Bachetti T, Confortini R. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure.
Circulation
 .
1995
;
92
:
1479
–1486
10
Pousset
F
, Isnard R, Lechat P. Prognostic value of plasma endothelin-1 in patients with chronic heart failure.
Eur Heart J
 .
1997
;
18
:
254
–258
11
Blaschko
H
, Comline RC, Schneider F, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation.
Nature
 .
1967
;
215
:
58
–59
12
Winkler
H
, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives.
Neuroscience
 .
1992
;
49
:
497
–528
13
Huttner
WB
, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family.
Trends Biochem Sci
 .
1991
;
16
:
27
–30
14
Mouland
AJ
, Bevan S, White JH, Hendy GN. Human chromogranin-A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression.
Biol Chem
 .
1994
;
269
:
6918
–6926
15
Takiyyuddin
MA
, Cervenka JH, Sullivan PA. Is physiologic sympathoadrenal catecholamine release exocytotic in humans?
Circulation
 .
1990
;
81
:
185
–195
16
Cryer
PE
, Wortsman J, Shah SD, Nowak RM, Deftos LJ. Plasma chromogranin-A as a marker of sympathochromaffin activity in humans.
Am J Physiol
 .
1991
;
260
:
E243
–E246
17
Takiyyuddin
MA
, Brown MR, Dinh TQ. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release.
J Auton Pharmacol
 .
1994
;
14
:
187
–200
18
O'Connor
DT
, Bernstein KN. Radioimmunoassay of chromogranin-A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma.
N Engl J Med
 .
1984
;
311
:
764
–770
19
O'Connor
DT
, Deftos LJ. Secretion of chromogranin-A by peptide-producing endocrine neoplasms.
N Engl J Med
 .
1986
;
314
:
1145
–1151
20
Deftos
LJ
. Chromogranin-A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker.
Endocr Rev
 .
1991
;
12
:
181
–187
21
Schiller
NB
, Shah PM, Crawford M. Recommendation for quantification of the left ventricle by two-dimensional echocardiography.
J Am Soc Echocardiogr
 .
1989
;
5
:
358
–367
22
Eur Heart J
 .
1997
;
18
:
1247
–1254
23
Anand
IS
, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure.
Circulation
 .
1989
;
80
:
299
–305
24
Ceconi
C
, Condorelli E, Quinzanini M, Rodella A, Ferrari R, Harris P. Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure.
Cardiovasc Res
 .
1989
;
23
:
674
–682
25
Poiesi
C
, Rodella A, Mantero G, Cannella G, Ferrari R, Albertini A. Improved radioimmunoassay of atrial natriuretic peptide in plasma.
Clin Chem
 .
1989
;
35
:
1431
–1434
26
Carmichael
SW
, Stoddard SL, O'Connor DT, Yaksh TL, Tyce GM. The secretion of catecholamines, chromogranin-A and neuropeptide Y from the adrenal medulla of the cat via the adrenolumbar vein and thoracic duct: different anatomic routes based on size.
Neuroscience
 .
1990
;
34
:
433
–440
27
Hsiao
RJ
, O'Connor DT, Barbosa JA, Parmer RJ, Newmann HP. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution.
Am J Med
 .
1990
;
88
:
607
–613
28
O'Connor
DT
, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure.
Clin Chem
 .
1989
;
35
:
1631
–1637
29
Corti
A
, Longhi R, Gasparri A, Chen F, Pelagi M, Siccardi AG. Antigenic regions of human chromogranin-A and their topographic relationships with structural/functional domains.
Eur J Biochem
 .
1996
;
235
:
275
–280
30
Mudge
GH
, Goldstein S, Addonizio LJ. Task Force 3: Recipient Guidelines/Prioritization.
J Am Coll Cardiol
 .
1993
;
22
:
21
–31
31
Akaike
H
. A new look at statistical model identification.
IEEE Transaction on Automatic Control
 .
1974
;
19
:
716
–722
32
Lindberg
I
. The new eukaryotic precursor processing proteinases.
Mol Endocrinol
 .
1991
;
5
:
1361
–1365
33
Metz-Boutigue
MH
, Garcia-Sablone P, Hogue-Angeletti R, Aunis D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites.
Eur J Biochem
 .
1993
;
217
:
247
–257
34
Curry
WJ
, Johnston CF, Hutton JC. The tissue distribution of rat chromogranin A-derived peptides: evidence for differential tissue processing from sequence specific antisera.
Histochemistry
 .
1991
;
96
:
531
–538
35
Laslop
A
, Doblinger A, Weiss U. Proteolytic processing of Chromogranins. Helle KB, Aunis D. Chromogranins: Functional and Clinical Aspects. New York: Kluwer Academic/Plenum Publishers; 2000. p. 155–166
36
Tatemoto
K
, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion.
Nature
 .
1986
;
324
:
476
–478
37
Fasciotta
BH
, Trauss CA, Greeley GH, Cohn DV. Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion.
Endocrinology
 .
1993
;
133
:
461
–466
38
Mahata
SK
, O'Connor DT, Mahata M. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist.
J Clin Invest
 .
1997
;
100
:
1623
–1633
39
Parmer
RJ
, Mahata M, Gong Y. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion.
J Clin Invest
 .
2000
;
106
:
907
–915
40
Helle
KB
, Angeletti RH. Chromogranin-A: a multipurpose pro-hormone?
Acta Physiol Scand
 .
1994
;
152
:
1
–10
41
Aardal
S
, Helle KB. The vasoinhibitory activity of bovine chromogranin—A fragment (vasostatin) and its independence from extracellular calcium in isolated segments of human blood vessels.
Regul Pept
 .
1992
;
41
:
9
–18
42
Aardal
S
, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin-A, suppress tension in isolated human blood vessel segments.
J Neuroendocrinol
 .
1993
;
5
:
405
–412
43
Helle
KB
. Vasostatins. Helle KB, Aunis D. Chromogranins: Functional and Clinical Aspects. New York: Kluwer Academic/Plenum Publishers; 2000. p. 225–238
44
Gasparri
A
, Sidoli A, Perez Sanchez L. Chromogranin A fragments modulate cell adhesion. identification and characterisation of a pro-adhesive domain.
J Biol Chem
 .
1997
;
272
:
20835
–20843
45
Ratti
S
, Curnis F, Longhi R. Structure–activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells.
J Biol Chem
 .
2000
;
275
:
29257
–29263
46
Hall
C
, Rouleau JL, Moyè L. N-terminal Proatrial Natriuretic Factor. An independent predictor of long-term prognosis after myocardial infarction.
Circulation
 .
1994
;
89
:
1934
–1942
47
McDonagh
TA
, Morrison CE, Lawrence A. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population.
Lancet
 .
1997
;
350
:
829
–833
48
Cowie
MR
, Struthers AD, Wood DA. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.
Lancet
 .
1997
;
350
:
1349
–1353
49
Monge
JC
. Neurohormonal markers of clinical outcome in cardiovascular disease: Is endothelin the best one?
J Cardiovasc Pharmacol
 .
1998
;
32
:
S36
–S42

Comments

0 Comments